Sarepta Therapeutics, Inc. Earnings

Sarepta Therapeutics, Inc.’s revenue jumped 65.94% since last year same period to $658.41Mn in the Q4 2024. On a quarterly growth basis, Sarepta Therapeutics, Inc. has generated 40.94% jump in its revenue since last 3-months.

Sarepta Therapeutics, Inc.’s net profit jumped 248.37% since last year same period to $159.05Mn in the Q4 2024. On a quarterly growth basis, Sarepta Therapeutics, Inc. has generated 373.21% jump in its net profits since last 3-months.

Sarepta Therapeutics, Inc.’s net profit margin jumped 109.94% since last year same period to 24.16% in the Q4 2024. On a quarterly growth basis, Sarepta Therapeutics, Inc. has generated 235.76% jump in its net profit margins since last 3-months.

Sarepta Therapeutics, Inc.’s price-to-earnings ratio after this Q4 2024 earnings stands at 44.04.

Sarepta Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at 2.06 - a 1684.85% jump from last quarter’s estimates.

Sarepta Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at 2.06.

Sarepta Therapeutics, Inc.’s earning per share (EPS) jumped 304.26% since last year same period to 1.9 in the Q4 2024. This indicates that the Sarepta Therapeutics, Inc. has generated 304.26% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Sarepta Therapeutics, Inc.’s return on assets (ROA) stands at 0.04.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Sarepta Therapeutics, Inc.’s return on equity (ROE) stands at 0.2.